Cardiogenic shock
(Unterschied zwischen Versionen)
| Zeile 1: | Zeile 1: | ||
| + | {{tp|p=32471815|t=2020. Epinephrine use in COVID-19: friend or foe?|pdf=|usr=007}} | ||
{{tp|p=32453250|t=2020. Why the Use of Angiotensin II May Be a Fatal Mistake in Covid-19.|pdf=|usr=007}} | {{tp|p=32453250|t=2020. Why the Use of Angiotensin II May Be a Fatal Mistake in Covid-19.|pdf=|usr=007}} | ||
{{tp|p=32503621|t=2020. Angiotensin II administration to COVID-19 patients is not advisable.|pdf=|usr=007}} | {{tp|p=32503621|t=2020. Angiotensin II administration to COVID-19 patients is not advisable.|pdf=|usr=007}} | ||
Version vom 22. Juni 2020, 14:39 Uhr
32471815 2020. Epinephrine use in COVID-19: friend or foe?
32453250 2020. Why the Use of Angiotensin II May Be a Fatal Mistake in Covid-19.
32503621 2020. Angiotensin II administration to COVID-19 patients is not advisable.
32209811 2020. Angiotensin II for the Treatment of COVID-19?Related Vasodilatory Shock
C7172437 2020. Effective Use of Angiotensin II in Coronavirus Disease 19?Associated Mixed Shock State: A Case Report
32363334 ä. Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
| 32386565 2020. Hyperinflammatory shock in children during COVID-19 pandemic |
C7184000 ä. COVID-19 and cardiogenic shock Different cardiovascular presentations with high mortality
